New England Journal of Medicine· 2016Q1

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel et al.

1,436citations
Q1SCImago
2016year

Short summary

Adding daratumumab to lenalidomide and dexamethasone significantly extended progression-free survival by 7.5 months in patients with relapsed or refractory multiple myeloma (median 26.1 vs. 18.6 months).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine